| Serial Number | 79410373 |
| Word Mark | LIGACHEM |
| Filing Date | Friday, September 6, 2024 |
| Status | 661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED |
| Status Date | Tuesday, April 8, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | NOT AVAILABLE |
| Description of Mark | The mark consists of a DNA symbol design in orange, dark grey and light grey, made using two vertically interlocking hexagons followed by the wording "LigaChem". The left side of the upper hexagon is orange and resembles the letter "L" with light grey horizontal lines on the right, and the left side of the bottom hexagon is comprised of light grey horizontal lines with dark grey on the right resembling the reversed letter "C", all followed by the wording LigaChem in stylized black letters. The color white visible through the mark represents background only and is not part of the mark. |
| Indication of Colors claimed | The color(s) orange, dark grey, light grey and black is/are claimed as a feature of the mark. |
| Goods and Services | Research and development of vaccines and medicines; biomedical research services; biological research and analysis; medical research in the field of crude drugs; biochemical research and analysis; bacteriological research and analysis; drug discovery services; research and development of medicines; biotechnology research; development of pharmaceutical preparations and medicines; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; laboratory research in the field of pharmaceuticals; pharmaceutical drug development services; pharmaceutical research and development; pharmaceutical drug development services; consultancy pertaining to pharmacology; research in the field of pharmaceuticals; scientific research for medical purposes in the field of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; medical research services; medical research laboratory services; research of medicines; platform as a service (PAAS) featuring computer software platforms for research and development in the field of pharmaceuticals, biotechnology and medicine; laboratory research services relating to pharmaceuticals; research services in the field of pharmaceutical preparations; testing of pharmaceuticals; clinical research in the field of medicine; chemical research and analysis. |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, December 2, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | LigaChem Biosciences Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Event Date | Event Description |
| Thursday, November 21, 2024 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Monday, December 2, 2024 | LIMITATION FROM ORIGINAL APPLICATION ENTERED |
| Thursday, December 5, 2024 | APPLICATION FILING RECEIPT MAILED |
| Thursday, December 5, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, February 12, 2025 | ASSIGNED TO EXAMINER |
| Wednesday, February 19, 2025 | NON-FINAL ACTION WRITTEN |
| Wednesday, February 19, 2025 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Wednesday, March 26, 2025 | REFUSAL PROCESSED BY MPU |
| Wednesday, March 26, 2025 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Tuesday, April 8, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, April 8, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, April 8, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |